文献速递糖尿病

1型糖尿病不同发展阶段口服葡萄糖后胰高血糖素反应的变化

Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本横断面研究纳入47名4至25岁来自芬兰DIPP研究的受试者,按胰岛自身抗体状态及1型糖尿病1至3期分组,在6点口服葡萄糖耐量试验中检测胰高血糖素等指标。结果显示空腹胰高血糖素水平随疾病进展升高,且仅早期3期患者出现15分钟胰高血糖素反常升高。

要点

  • 空腹胰高血糖素水平随1型糖尿病疾病进展而升高。
  • 仅早期3期患者OGTT 15分钟出现胰高血糖素反常升高。
  • 需前瞻性研究阐明α细胞在疾病进展中的作用。

核心结论

  • 1型糖尿病不同发展阶段口服葡萄糖后胰高血糖素反应模式存在差异,早期3期出现15分钟反常升高。

研究设计与样本

  • 横断面研究,纳入47名4至25岁芬兰DIPP研究参与者,按胰岛自身抗体状态及1型糖尿病1至3期分组。
  • 进行6点口服葡萄糖耐量试验,用常规放射免疫法检测胰高血糖素,同时检测胰岛素、C肽、葡萄糖和GLP-1。

主要发现

  • 空腹血浆胰高血糖素水平随疾病进展升高。
  • 各组间OGTT期间胰高血糖素浓度纵向模式差异显著。
  • 仅早期3期1型糖尿病个体出现15分钟胰高血糖素反常升高。

临床怎么用

  • 提示关注1型糖尿病早期3期α细胞功能异常,支持测试改善α和β细胞功能的药物疗法。

局限性

  • 横断面设计无法确定因果关系,需前瞻性研究进一步阐明α细胞在疾病进展中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Autoimmune destruction of β cells and their functional decline precedes the clinical onset of type 1 diabetes. However, altered α-cell function and hyperglucagonemia may contribute to the development of hyperglycemia and ketoacidosis at onset. OBJECTIVE: In this cross-sectional study, we analyzed glucagon concentrations during an oral glucose tolerance test (OGTT) in individuals at the early stages of type 1 diabetes to understand the role of α-cell function in the disease process. METHODS: We recruited 47 participants, aged 4 to 25 years, from the Finnish Diabetes Prediction and Prevention (DIPP) study, and categorized them into the following groups: islet autoantibody (IAb) negative, single IAb positive, and stages 1 to 3 of type 1 diabetes. Glucagon levels were measured during a 6-point OGTT using a conventional radioimmunoassay, alongside insulin, C-peptide, glucose, and glucagon-like peptide-1 (GLP-1). RESULTS: Fasting plasma glucagon levels increased with disease progression. The longitudinal patterns of glucagon concentrations during the OGTT differed significantly between groups, with a paradoxical 15-minute glucagon increase observed only in individuals at early stage 3 of type 1 diabetes. CONCLUSION: These findings highlight the need for prospective studies to further elucidate the role of α cells in disease progression and support testing pharmacotherapies aimed at improving both α- and β-cell functions during disease development.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kontola H, Crisóstomo L, Löyttyniemi E, et al. Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development. J Clin Endocrinol Metab. 2026. PMID: 41172278. doi:10.1210/clinem/dgaf601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。